Apollo Therapeutics is a pioneering biopharmaceutical company focused on translating breakthrough scientific discoveries from leading academic institutions into transformative medicines. They operate a portfolio-based model, identifying and advancing a diverse range of novel therapeutic programs across various disease areas with high unmet medical needs. Apollo aims to accelerate the development of innovative treatments by providing deep scientific, clinical, and financial expertise to its programs.
Serves as the central hub for strategic leadership, global R&D program oversight, corporate development, financial operations, and administrative functions.
Located within Granta Park, a leading European life science campus, providing access to state-of-the-art laboratory and office facilities and fostering collaboration within a dynamic biotech ecosystem.
Characterized by a science-driven, innovative, and collaborative environment. The culture emphasizes rigorous scientific research, entrepreneurial thinking, and a patient-centric approach to drug discovery and development.
The UK headquarters in the Cambridge biotech cluster offers strategic advantages, including access to world-class academic research institutions, a highly skilled talent pool, and an extensive network of pharmaceutical and biotech partners.
Apollo Therapeutics has a strategic global footprint with primary operations in two of the world's leading biotechnology centers: Cambridge, United Kingdom, and Cambridge, Massachusetts, USA. This dual presence enables the company to access premier scientific talent, cutting-edge research, and investment opportunities on both sides of the Atlantic. Key global functions supported include R&D program management, clinical development, business development, academic collaborations, and corporate strategy.
Granta Park, Great Abington
Cambridge
Cambridgeshire
United Kingdom
Address: One Kendall Square, Building 1400W, Suite 14-203, Cambridge, MA 02139, USA
Focuses on leveraging North American scientific innovation, engaging with US-based academic partners and investigators, supporting US-centric clinical trial activities, and fostering relationships with the US investment community.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Apollo Therapeutics' leadership includes:
Apollo Therapeutics has been backed by several prominent investors over the years, including:
Apollo Therapeutics has notably strengthened its executive leadership team over the past 12 months with key appointments in finance and business operations. These hires are aimed at steering the company through its next phase of growth and pipeline advancement. No major executive departures have been publicly announced during this period.
Discover the tools Apollo Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While Apollo Therapeutics' exact email format policy isn't publicly detailed, common corporate email patterns for biopharmaceutical companies include [first_initial][last]@[companydomain.com] (e.g., jsmith@apollotherapeutics.com) or [first].[last]@[companydomain.com] (e.g., jane.doe@apollotherapeutics.com). The specific format can vary.
[first_initial][last]@apollotherapeutics.com
Format
rmason@apollotherapeutics.com
Example
80%
Success rate
Business Wire • January 9, 2024
Apollo Therapeutics announced the appointment of Scott Megaffin as its new Chief Business Officer. Mr. Megaffin brings over 25 years of extensive experience in the biopharmaceutical industry, tasked with leading Apollo's business development and corporate strategy efforts....more
Business Wire • September 20, 2023
Apollo Therapeutics successfully closed an upsized $226.5 million Series C financing round. The funding was co-led by Patient Square Capital and M&G Investments, with strong participation from other new and existing investors. These funds are dedicated to advancing its diverse portfolio of therapeutic programs....more
Business Wire • July 11, 2023
Apollo Therapeutics announced the strategic appointment of Rob James, Ph.D., as its Chief Financial Officer. Dr. James will be responsible for overseeing the company's financial strategy, planning, and operations as it continues to advance its innovative pipeline....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Apollo Therapeutics, are just a search away.